1
|
El Maassarani M, Barbarin A, Fromont G, Kaissi O, Lebbe M, Vannier B, Moussa A, Séité P. Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression. PLoS One 2016; 11:e0155950. [PMID: 27191720 PMCID: PMC4871423 DOI: 10.1371/journal.pone.0155950] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Accepted: 05/07/2016] [Indexed: 01/13/2023] Open
Abstract
The EGF-family of tyrosine-kinase receptors activates cytoplasmic pathways involved in cell proliferation, migration and differentiation in response to specific extracellular ligands. Beside these canonical pathways, the nuclear localization of the ErbB receptors in primary tumours and cancer cell lines led to investigate their role as transcriptional regulators of cancer genes. The nuclear localization of ErbB3 has been reported in various cancer tissues and cell lines but the nuclear functions and the putative correlation with tumour progression and resistance to therapy remain unclear. We first assessed ErbB3 expression in normal and tumour prostate tissues. The nuclear staining was mainly due to an isoform matching the C-terminus domain of the full length ErbB3185kDa receptor. Nuclear staining was also restricted to cancer cells and was increased in advanced castration-resistant prostate cancer when compared to localized tumours, suggesting it could be involved in the progression of prostate cancer up to the terminal castration-resistant stage. ChIP-on-chip experiments were performed on immortalized and tumour cell lines selected upon characterization of endogenous nuclear expression of an ErbB380kDa isoform. Among the 1840 target promoters identified, 26 were selected before ErbB380kDa-dependent gene expression was evaluated by real-time quantitative RT-PCR, providing evidence that ErbB380kDa exerted transcriptional control on those genes. Some targets are already known to be involved in prostate cancer progression even though no link was previously established with ErbB3 membrane and/or nuclear signalling. Many others, not yet associated with prostate cancer, could provide new therapeutic possibilities for patients expressing ErbB380kDa. Detecting ErbB380kDa could thus constitute a useful marker of prognosis and response to therapy.
Collapse
Affiliation(s)
- Mahmoud El Maassarani
- Equipe 2RCT, Université de Poitiers, Faculté des Sciences Fondamentales, Pôle Biologie- Santé, 1 rue G. Bonnet, 86073, Poitiers cedex 9, France
| | - Alice Barbarin
- Equipe 2RCT, Université de Poitiers, Faculté des Sciences Fondamentales, Pôle Biologie- Santé, 1 rue G. Bonnet, 86073, Poitiers cedex 9, France
| | - Gaëlle Fromont
- Centre Hospitalier Universitaire Bretonneau, Laboratoire d'Anatomopathologie, INSERM U1069, 37000 Tours, France
| | - Ouafae Kaissi
- LTI Laboratory, Abdelmalek Essaadi University, ENSAT, BP 1818, 90 000 Tangier, Morocco
| | - Margot Lebbe
- Equipe 2RCT, Université de Poitiers, Faculté des Sciences Fondamentales, Pôle Biologie- Santé, 1 rue G. Bonnet, 86073, Poitiers cedex 9, France
| | - Brigitte Vannier
- Equipe 2RCT, Université de Poitiers, Faculté des Sciences Fondamentales, Pôle Biologie- Santé, 1 rue G. Bonnet, 86073, Poitiers cedex 9, France
| | - Ahmed Moussa
- LTI Laboratory, Abdelmalek Essaadi University, ENSAT, BP 1818, 90 000 Tangier, Morocco
| | - Paule Séité
- Equipe 2RCT, Université de Poitiers, Faculté des Sciences Fondamentales, Pôle Biologie- Santé, 1 rue G. Bonnet, 86073, Poitiers cedex 9, France
| |
Collapse
|
2
|
Barbarin A, Séité P, Godet J, Bensalma S, Muller JM, Chadéneau C. Atypical nuclear localization of VIP receptors in glioma cell lines and patients. Biochem Biophys Res Commun 2014; 454:524-30. [DOI: 10.1016/j.bbrc.2014.10.113] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Accepted: 10/23/2014] [Indexed: 12/27/2022]
|
3
|
Barbarin A, Séité P, Bensalma S, Muller J, Chadeneau C. 650: Atypical nuclear localization of VIP receptors in glioma cell lines and patients. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50570-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Dichamp I, Séité P, Agius G, Barbarin A, Beby-Defaux A. Human papillomavirus 16 oncoprotein E7 stimulates UBF1-mediated rDNA gene transcription, inhibiting a p53-independent activity of p14ARF. PLoS One 2014; 9:e96136. [PMID: 24798431 PMCID: PMC4010441 DOI: 10.1371/journal.pone.0096136] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Accepted: 04/03/2014] [Indexed: 11/18/2022] Open
Abstract
High-risk human papillomavirus oncoproteins E6 and E7 play a major role in HPV-related cancers. One of the main functions of E7 is the degradation of pRb, while E6 promotes the degradation of p53, inactivating the p14ARF-p53 pathway. pRb and p14ARF can repress ribosomal DNA (rDNA) transcription in part by targeting the Upstream Binding Factor 1 (UBF1), a key factor in the activation of RNA polymerase I machinery. We showed, through ectopic expression and siRNA silencing of p14ARF and/or E7, that E7 stimulates UBF1-mediated rDNA gene transcription, partly because of increased levels of phosphorylated UBF1, preventing the inhibitory function of p14ARF. Unexpectedly, activation of rDNA gene transcription was higher in cells co-expressing p14ARF and E7, compared to cells expressing E7 alone. We did not find a difference in P-UBF1 levels that could explain this data. However, p14ARF expression induced E7 to accumulate into the nucleolus, where rDNA transcription takes place, providing an opportunity for E7 to interact with nucleolar proteins involved in this process. GST-pull down and co-immunoprecipitation assays showed interactions between p14ARF, UBF1 and E7, although p14ARF and E7 are not able to directly interact. Co-expression of a pRb-binding-deficient mutant (E7C24G) and p14ARF resulted in EC24G nucleolar accumulation, but not in a significant higher activation of rDNA transcription, suggesting that the inactivation of pRb is involved in this phenomenon. Thus, p14ARF fails to prevent E7-mediated UBF1 phosphorylation, but could facilitate nucleolar pRb inactivation by targeting E7 to the nucleolus. While others have reported that p19ARF, the mouse homologue of p14ARF, inhibits some functions of E7, we showed that E7 inhibits a p53-independent function of p14ARF. These results point to a mutually functional interaction between p14ARF and E7 that might partly explain why the sustained p14ARF expression observed in most cervical pre-malignant lesions and malignancies may be ineffective.
Collapse
Affiliation(s)
- Isabelle Dichamp
- Unité de Virologie, Centre Hospitalier Universitaire de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France
| | - Paule Séité
- Equipe Emergente 2RCT «Récepteurs, Régulations, Cellules Tumorales», Université de Poitiers, Poitiers, France
| | - Gérard Agius
- Unité de Virologie, Centre Hospitalier Universitaire de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France
| | - Alice Barbarin
- Equipe Emergente 2RCT «Récepteurs, Régulations, Cellules Tumorales», Université de Poitiers, Poitiers, France
| | - Agnès Beby-Defaux
- Unité de Virologie, Centre Hospitalier Universitaire de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France
- Equipe Emergente 2RCT «Récepteurs, Régulations, Cellules Tumorales», Université de Poitiers, Poitiers, France
- * E-mail:
| |
Collapse
|
5
|
Andrique L, Fauvin D, El Maassarani M, Colasson H, Vannier B, Séité P. ErbB380kDa, a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF. Cell Signal 2012; 24:1074-85. [DOI: 10.1016/j.cellsig.2012.01.002] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Revised: 12/16/2011] [Accepted: 01/04/2012] [Indexed: 01/11/2023]
|
6
|
Ayrault O, Andrique L, Larsen CJ, Séité P. [The negative regulation of ribosome biogenesis: a new Arf-dependent pathway controlling cell proliferation?]. Med Sci (Paris) 2006; 22:519-24. [PMID: 16687121 DOI: 10.1051/medsci/2006225519] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The nucleolar Arf protein has initially been shown to regulate cell cycle through the so-called Arf-mdm2-p53 pathway. In addition to this well characterized pathway, convergent data published since 2000 indicate that Arf can inhibit cell proliferation in absence of p53, suggesting the existence of a p53-independent pathway. Several partners have recently been described that could participate in an alternative regulatory process. Recent results show that : (1) Arf binds the rDNA promoter to inhibit the transcription of the 47S rRNA precursor and (2) Arf interacts with the nucleophosmin/B23 protein to negatively regulate rRNA maturation, it is assumed that the tumour suppressor may downregulate the cell cycle progression through the control of ribosome biogenesis, thus resulting in completion of cell cycle arrest.
Collapse
Affiliation(s)
- Olivier Ayrault
- EA 3805, Equipe d'Oncologie Moléculaire, Pôle Biologie-Santé, 40, avenue du recteur Pineau, 86022 Poitiers Cedex, France
| | | | | | | |
Collapse
|
7
|
Ayrault O, Andrique L, Fauvin D, Eymin B, Gazzeri S, Séité P. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 2006; 25:7577-86. [PMID: 16924243 DOI: 10.1038/sj.onc.1209743] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The nucleolar Arf protein has been shown to regulate cell cycle through both p53-dependent and -independent pathways. In addition to the well-characterized Arf-mdm2-p53 pathway, several partners of Arf have recently been described that could participate in alternative regulation process. Among those is the nucleolar protein B23/NPM, involved in the sequential maturation of rRNA. p19ARF can interact with B23/NPM in high molecular complexes and partially inhibit the cleavage of the 32S rRNA, whereas the human p14ARF protein has been shown to participate in the degradation of NPM/B23 by the proteasome. These data led to define Arf as a negative regulator of ribosomal RNA maturation. Our recent finding that the human p14ARF protein was able to specifically interact with the rRNA promoter in a p53-independent context, led us to analyse in vitro and in vivo the consequences of this interaction. Luciferase assay and pulse-chase experiments demonstrated that the rRNA transcription was strongly reduced upon p14ARF overexpression. Investigations on potential interactions between p14ARF and the transcription machinery proteins demonstrated that the upstream binding factor (UBF), required for the initiation of the transcriptional complex, was a new partner of the p14ARF protein. We next examined the phosphorylation status of UBF as UBF phosphorylation is required to recruit on the promoter factors involved in the transcriptional complex. Upon p14ARF overexpression, UBF was found hypophosphorylated, thus unable to efficiently recruit the transcription complex. Taken together, these data define a new p53-independent pathway that could regulate cell cycle through the negative control of rRNA transcription.
Collapse
Affiliation(s)
- O Ayrault
- Laboratoire d'Oncologie Moléculaire. EA3805, Pô le Biologie-Santé. 40, Poitiers cedex, France
| | | | | | | | | | | |
Collapse
|
8
|
Cividin M, Ayrault O, Sorel N, Séité P, Brizard F, Blanchet O, Mahon FX, Guilhot F, Larsen C, Chomel JC, Brizard A. Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia. Leuk Res 2006; 30:1273-8. [PMID: 16533530 DOI: 10.1016/j.leukres.2006.02.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2005] [Revised: 02/01/2006] [Accepted: 02/02/2006] [Indexed: 10/24/2022]
Abstract
Expression of p14(ARF) and p16(INK4a) tumor suppressor genes was investigated in 109 patients with chronic myeloid leukemia (CML). The p14(ARF) and p16(INK4a) mRNA levels were significantly low in patients in chronic phase (CP) at presentation and high in patients treated with interferon-alpha (IFN-alpha), especially in non-responders. A moderate overexpression of p14(ARF) with a normal expression of p16(INK4a) was observed in imatinib-resistant patients. Although protein expression did not consistently match mRNA levels, a role for the two cell cycle regulators in the IFN-alpha signaling pathway is suggested as well as a relation with the resistance to IFN-alpha or imatinib therapy.
Collapse
|
9
|
Ayrault O, Andrique L, Séité P. Involvement of the transcriptional factor E2F1 in the regulation of the rRNA promoter. Exp Cell Res 2006; 312:1185-93. [PMID: 16510138 DOI: 10.1016/j.yexcr.2006.01.027] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2005] [Revised: 01/25/2006] [Accepted: 01/27/2006] [Indexed: 01/25/2023]
Abstract
p16INK4a-pRB-E2F and ARF-MDM2-p53 are two major tumor suppressor networks involved in cell proliferation control. The nucleolar ARF protein binds to MDM2 to activate the growth suppressive functions of p53, but can also exert its tumor suppressor activity independently of p53, through mechanisms involving other regulators: in that manner, p14ARF has been shown to inhibit the transcriptional activity of E2F1 in vitro, suggesting that the two pathways intersect with one another. More recently, ARF has been shown to inhibit ribosomal RNA processing, and to specifically interact with the rRNA promoter, suggesting a role in the regulation of both maturation and transcription processes. We show here that E2F1 can bind the rRNA promoter and modulate its activity through the interaction with two E2F1-binding sequences we have identified. The regulation of ribosome biogenesis appears as a major p53-independent process, which involves both ARF and E2F1 to control cell proliferation.
Collapse
Affiliation(s)
- Olivier Ayrault
- Laboratoire d'Oncologie Moléculaire, EA 3805, Pôle Biologie-Santé, 40, avenue du Recteur Pineau, 86022 Poitiers cedex, France
| | | | | |
Collapse
|
10
|
Andrique L, Ayrault O, Larsen CJ, Séité P. In vitro and in vivo analysis of the interaction between 5.8S rRNA and ARF protein reveal a new difference between murine p19ARF and human p14ARF. Oncogene 2005; 24:2580-4. [PMID: 15735732 DOI: 10.1038/sj.onc.1208457] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Both human and murine ARF proteins have been recently reported to impair rRNA maturation and ribosomes biogenesis through a p53-independent pathway. A specific interaction has been established between 5.8S rRNA and the murine p19ARF specie. We report here, by use of both in vitro and ChIP-RNA assays, the absence of any interaction between the human p14ARF and the homologous 5.8S rRNA. Our data are not consistent with the involvement of a 5.8S-p14ARF complex in ribosome biogenesis in man. Rather they suggest that the human protein does not require such an interaction to achieve a similar function. This result is a new argument in favour of functional differences between human and murine ARF proteins.
Collapse
Affiliation(s)
- Laëtitia Andrique
- EA 3805, Laboratoire d'Oncologie Moléculaire, Pôle Biologie-Santé, 40 avenue du Recteur Pineau, 86022 Poitiers Cedex, France
| | | | | | | |
Collapse
|
11
|
Ayrault O, Olivier A, Karayan L, Lucie K, Riou JF, Jean-François R, Larsen CJ, Christian-Jacques L, Séité P, Paule S. Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I. Oncogene 2003; 22:1945-54. [PMID: 12673200 DOI: 10.1038/sj.onc.1206214] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We recently reported an interaction between the p14(ARF) protein and human topoisomerase I (Topo I) resulting in the stimulation of the relaxation activity of Topo I. Our data showed that the complex between the two proteins was located within the nucleolus. In the present work, we have investigated the regions of p14(ARF) involved in this interaction by using targeted point mutagenesis and deletion mutants. A region encompassing exon 2-encoded sequence was required for physical binding of p14(ARF) to Topo I as well as for stimulatory activity of the enzyme. Exon 1 beta-encoded segment was not implicated in the interaction. Moreover, among p14(ARF) point mutants selected for their high conservation among different mammalian species, mutant p14(ARF) (RR87, 88AA) did not stimulate Topo I in spite of its association with the enzyme, suggesting its direct implication in the functional activity of ARF. In contrast, one mutant, p14(ARF) (R71A), was more efficient than wild-type protein to activate Topo I, suggesting that this residue is a key element to modulate Topo I activity. Finally, only ARF-Topo I complexes containing p14(ARF) exon 2 segment were found to be localized in the nucleolus, suggesting that this subnuclear location is linked to the biological function of the ARF-Topo I complex.
Collapse
Affiliation(s)
- Olivier Ayrault
- Institut de Biologie Moléculaire et d'Ingénierie Génétique, Poitiers, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Eymin B, Karayan L, Séité P, Brambilla C, Brambilla E, Larsen CJ, Gazzéri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41. [PMID: 11314038 DOI: 10.1038/sj.onc.1204220] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2000] [Revised: 12/22/2000] [Accepted: 01/03/2001] [Indexed: 12/31/2022]
Abstract
The INK4a/ARF locus which is frequently inactivated in human tumours encodes two different tumour suppressive proteins, p16(INK4a) and ARF. p16(INK4a) is a major component of the RB pathway. ARF is part of an ARF-mdm2-p53 network that exerts a negative control on hyperproliferative signals emanating from oncogenic stimuli. Among these is the transcription factor E2F1, a final effector of the RB pathway, that induces ARF expression. Recent data suggest that ARF function is not restricted to the p53 pathway. However, ARF target(s) implicated in this p53-independent function remains to be identified. We show that ARF is able to inhibit the proliferation of human cell lines independently of their p53 status. In this context, we demonstrate that ARF interacts physically with E2F1 and inhibits its transcriptional activity. Moreover, we show that mdm2 is required for the modulation of E2F1 activity by ARF. Beside the well-known p53 and mdm2 partners, these results identify E2F1 as a new ARF target. Thus, ARF can be viewed as a dual-acting tumour suppressor protein in both the p53 and RB pathways, further emphasizing its role in tumour surveillance.
Collapse
Affiliation(s)
- B Eymin
- Groupe de recherche sur le cancer du poumon, INSERM EMI 9924, Institut Albert Bonniot, 38706 La Tronche Cedex, France
| | | | | | | | | | | | | |
Collapse
|
13
|
Karayan L, Riou JF, Séité P, Migeon J, Cantereau A, Larsen CJ. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 2001; 20:836-48. [PMID: 11314011 DOI: 10.1038/sj.onc.1204170] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2000] [Revised: 11/03/2000] [Accepted: 12/12/2000] [Indexed: 11/09/2022]
Abstract
The ARF gene (p19(ARF) in mouse and p14(ARF) in man) has become a central actor of the cell cycle regulation process as it participates to the ARF-MDM2-p53 pathway and the Rb-E2F-1 pathway. By use of immunoprecipitation and Western blotting (IP/WB), we now show that ARF physically associates with topoisomerase I (Topo I). ARF-Topo I immune complexes were detected in SF9 insect cells infected with recombinant baculoviruses encoding the two genes as well as in 293 cells that express endogenously these proteins. Preparations of a GST-ARF recombinant protein stimulated the DNA relaxation activity of Topo I but, in contrast, had no effect on the decatenation activity of Topo II. The Topo I stimulation was also detected in cell extracts of SF9 cells expressing both proteins. A confocal microscopy study indicated that part of ARF and Topo I colocalized in the granular component structure of the nucleolus. As a whole, our data indicate that Topo I is a new partner of ARF and suggest that ARF is involved in cell reactions that require Topo I.
Collapse
Affiliation(s)
- L Karayan
- Laboratoire d'Oncologie Moléculaire, FRE 2224 CNRS, Poitiers Cedex, France
| | | | | | | | | | | |
Collapse
|
14
|
Séité P, Ruchaud S, Hillion J, Gendron MC, Bruland O, Ségal-Bendirdjian E, Doskeland SO, Lillehaug JR, Lanotte M. Ectopic expression of Bcl-2 switches over nuclear signalling for cAMP-induced apoptosis to granulocytic differentiation. Cell Death Differ 2000; 7:1081-9. [PMID: 11139282 DOI: 10.1038/sj.cdd.4400730] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The IPC-81 myeloid leukaemia cells undergo apoptosis rapidly after cAMP stimulation (6 h) and cell death is prevented by early over-expression of the cAMP-inducible transcription repressor ICER, that blocks cAMP-dependent nuclear signalling. Therefore, the expression of specific genes controlled by CRE-containing promoters is likely to determine cell fate. We now show that cAMP-induced cell death also is abrogated by the over-expression of the anti-apoptotic gene, Bcl-2. Contrary to ICER, Bcl-2 does not affect cAMP-signalling and allows the analysis of cAMP responses in death rescued cells. The Bcl-2 transfected cells treated with 8-CPT-cAMP were growth-arrested and thereafter cells embarked in granulocytic differentiation, with no additional stimulation. Neutrophilic polynuclear granulocytes benefited from a long life span in G0-G1 and remained functional (phagocytosis). This work demonstrates that, using anti-apoptosis regulators, 'death signals' could be exploited to trigger distinct biological responses. Indeed, cAMP signal can trigger several simultaneously developing biological programs, in the same cell, i.e., growth regulation, apoptosis and differentiation. This cell system should prove useful to determine how a tumour cell can be re-programmed for either apoptosis or functional maturation by physiological signals.
Collapse
Affiliation(s)
- P Séité
- INSERM U496, Institut d'Hématologie, Hôpital St Louis, 75010-Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Séité P, Hillion J, d'Agay MF, Berger R, Larsen CJ. BCL2 complex rearrangement in follicular lymphoma: translocation mbr/JH and deletion in the vcr region of the same BCL2 allele. Oncogene 1993; 8:3073-80. [PMID: 8414508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Two rearrangements affecting the same allele of the BCL2 gene were characterized by molecular analysis of an untreated follicular lymphoma. The first rearrangement interested the major breakpoint region (mbr) on chromosome 18 and a JH segment on chromosome 14. The other one was located at the 5' end of the BCL2 gene, in the so called variant cluster region (vcr), and consisted of a series of deletions that removed part of a DNA region where initiation of transcription normally occurs. Interestingly, both rearrangements involved the same BCL2 allele. The simultaneous presence of mbr (or mcr) translocations and of minor rearrangements in vcr has been previously suggested by restriction map analysis in a significant number of follicular lymphomas. The significance of these abnormalities on the oncogenic process is discussed.
Collapse
Affiliation(s)
- P Séité
- Unité 301 INSERM, Institut de Génétique Moléculaire, Paris, France
| | | | | | | | | |
Collapse
|
16
|
Séité P, Hillion J, Leroux D, Berger R, Larsen CJ. Common sequence in chromosome translocations affecting B- and T-cell malignancies: a novel recombination site? Genes Chromosomes Cancer 1993; 6:253-4. [PMID: 7685632 DOI: 10.1002/gcc.2870060413] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
MESH Headings
- Base Sequence
- Chromosomes, Human, Pair 18/ultrastructure
- Chromosomes, Human, Pair 22/ultrastructure
- Consensus Sequence
- DNA Nucleotidyltransferases/metabolism
- Gene Rearrangement, B-Lymphocyte
- Gene Rearrangement, T-Lymphocyte
- Humans
- Leukemia-Lymphoma, Adult T-Cell/genetics
- Lymphoma, Follicular/genetics
- Molecular Sequence Data
- Sequence Alignment
- Sequence Homology, Nucleic Acid
- Translocation, Genetic
- VDJ Recombinases
Collapse
|
17
|
Séité P, Hillion J, d'Agay MF, Gaulard P, Cazals D, Badoux F, Berger R, Larsen CJ. BCL2 gene activation and protein expression in follicular lymphoma: a report on 64 cases. Leukemia 1993; 7:410-7. [PMID: 8383256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Rearrangements of the BCL2 gene and expression of bcl-2 protein were analyzed in a series of 64 cases of follicular lymphomas in order to establish a relationship between the rearrangements and the protein overexpression. Of the 64 cases, 41 showed BCL2 rearrangement involving one of the three breakpoint clusters: 30 in mbr, eight in mcr, and three in vcr. A double rearrangement mbr+vcr was detected in two cases. Twenty cases with bcl-2 protein expression in tumor cells exhibited no apparent rearrangement, suggesting the possible existence of other mechanisms activating the gene. Interestingly, expression of the LMP1 protein, the Epstein-Barr virus (EBV) encoded gene, whose capacity to induce BCL2 has been recently demonstrated, was only found in 2/41 cases in which BCL2 was rearranged. These data suggest that EBV infection is not an important mechanism in the activation of BCL2 in follicular lymphoma.
Collapse
Affiliation(s)
- P Séité
- Unité 301-INSERM, Institut de Génétique Moléculaire, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|